Survival Benefits of Immune Checkpoint Inhibito...

By João L. Carapinha

March 21, 2025

A recent cohort study examined factors associated with immune checkpoint inhibitors (ICIs) treatment and outcomes in 18,932 metastatic colorectal cancer (mCRC) patients. Patients with microsatellite instability-high (MSI-H) tumors who received ear...
FDA Warning Aspen Pharmacare: Evaluating Compliance Violations and Their Impact
Pharmaceutical Innovation and Market Access: Insights from Fast Company’s 202...
Global Partnerships SCD in Africa
Molecular Insights into Angiogenesis in Colorectal Cancer
Hypertension in Young South African Adults
CKD Prevalence in HIV Patients on TDF: A Global Perspective
South Africa Launches Patient-Led Cancer Registry
Advancing Cancer Treatment: Ivonescimab’s Potential and Strategic Collaborati...
Global Childhood Cancer Access
New Global AIDS Strategy 2030 Aims to End AIDS Threat by 2030
Lenacapavir HIV Prevention: Approval and Access Strategy Updates
Strengthening Africa Health Partnership